Effect of interferon-αα2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes

Xenobiotica

Volumn 41, Issue 6, 2011, Pages 476-485

  Chen, Cliff ^a   Han, Yong Hae ^a   Yang, Zheng ^a   Rodrigues, A David ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Hepatocyte; interferon 2b

Indexed keywords

ADIPOPHILIN; ALPHA2B INTERFERON; BREAST CANCER RESISTANCE PROTEIN; CARBOXYESTERASE 2; CARBOXYLESTERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 2B7; GLYCOPROTEIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING PEPTIDE 1B1; ORGANIC ANION TRANSPORTING PEPTIDE 1B3; ORGANIC ANION TRANSPORTING PEPTIDE 2B1; ORGANIC CATION TRANSPORTER 1; PHENOBARBITAL; PYRUVATE DEHYDROGENASE KINASE 4; RIFAMPICIN; STAT1 PROTEIN; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 2A1; UNCLASSIFIED DRUG;

ARTICLE; COCULTURE; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; LIVER PARENCHYMA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 79956352358     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.560971     Document Type: Article

References (49)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A. (1993). Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715. (Pubitemid 23317282)
2. Aitken AE, Morgan ET. (2007). Gene-specifc efects of infammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687-1693. (Pubitemid 47296065)
3. Aouabdi S, Gibson G, Plant N. (2006). Transcriptional regulation of the PXR gene: identifcation and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos 34:138-144. (Pubitemid 43042655)
4. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK. (1991). Te interferons. Mechanisms of action and clinical applications. JAMA 266:1375-1383.
5. Becquemont L, Chazouilleres O, Serfaty L, Poirier JM, Broly F, Jaillon P, Poupon R, Funck-Brentano C. (2002). Efect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ter 71:488-495. (Pubitemid 34701356)
6. Bojes HK, Turman RG. (1996). Peroxisome proliferators activate Kupfer cells in vivo. Cancer Res 56:1-4. (Pubitemid 26010375)
7. Brockmeyer NH, Barthel B, Mertins L, Goos M. (1998). Changes of antipyrine pharmacokinetics during infuenza and after administration of interferon-alpha and-beta. Int J Clin Pharmacol Ter 36:309-311. (Pubitemid 28271548)
8. CL. (2007). Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. J Leukoc Biol 81:825-834. (Pubitemid 46393561)
9. Chetty M, Murray M. (2007). CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 8:307-313. (Pubitemid 46780060)
10. Craig PI, Mehta I, Murray M, McDonald D, Aström A, van der Meide PH, Farrell GC. (1990). Interferon down regulates the male-specifc cytochrome P450IIIA2 in rat liver. Mol Pharmacol 38:313-318. (Pubitemid 20291568)
11. Dalen KT, Ulven SM, Arntsen BM, Solaas K, Nebb HI. (2006). PPARalpha activators and fasting induce the expression of adipose diferentiation-related protein in liver. J Lipid Res 47:931-943. (Pubitemid 43778694)
12. Deterding K, Grüngreif K, Lankisch TO, Potthof A, Bahr MJ, Manns MP, Wedemeyer H, Strassburg CP. (2009). Gilbert's syndrome and antiviral therapy of hepatitis C. Ann Hepatol 8:246-250.
13. Donato MT, Herrero E, Gómez-Lechón MJ, Castell JV. (1993). Inhibition of monooxygenase activities in human hepatocytes by interferons. Toxicol In Vitro 7:481-485.
14. Farrar MA, Schreiber RD. (1993). Te molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571-611. (Pubitemid 23115018)
15. Gordon CP, Keller PA. (2005). Control of hepatitis C: a medicinal chemistry perspective. J Med Chem 48:1-20. (Pubitemid 40105243)
16. Grubisic-Cabo F, Vrdoljak E. (2006). Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfbrozil in therapy. Med Oncol 23:121-124. (Pubitemid 43787125)
17. Ha HR, Chen J, Freiburghaus AU, Follath F. (1995). Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 39:321-326.
18. Haque SJ, Williams BR. (1998). Signal transduction in the interferon system. Semin Oncol 25:14-22. (Pubitemid 28093151)
19. Hasmall S, James N, Hedley K, Olsen K, Roberts R. (2001). Mouse hepatocyte response to peroxisome proliferators: dependency on hepatic nonparenchymal cells and peroxisome proliferator activated receptor alpha (PPARalpha). Arch Toxicol 75:357-361. (Pubitemid 32757417)
20. Hassan M, Nilsson C, Olsson H, Lundin J, Osterborg A. (1999). Te infuence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. Eur J Haematol 63:163-170. (Pubitemid 29406733)
21. Islam M, Frye R F, Richards TJ, Sbeitan I, Donnelly SS, Glue P, Agarwala SS, Kirkwood JM. (2002). Diferential efect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 8:2480-2487. (Pubitemid 34856329)
22. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI. (1993). Efects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 36:229-235. (Pubitemid 23275340)
23. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. (2006). Diferential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756-1763. (Pubitemid 44427479)
24. Jonkman JH, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, De Noord OE, Guentert TW. (1989). Efects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 27:795-802. (Pubitemid 19179518)
25. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM. (1998). Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 46:563-570. (Pubitemid 28522120)
26. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. (2005). Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 33:619-622. (Pubitemid 40593874)
27. Le Vee M, Gripon P, Stieger B, Fardel O. (2008). Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinfammatory cytokine interleukin 1beta. Drug Metab Dispos 36:217-222. (Pubitemid 351185762)
28. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE 3rd. (2004). Multiparametric fow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon alfa immunotherapy. J Natl Cancer Inst 96:1331-1342. (Pubitemid 39264122)
29. MacQuillan GC, Mamotte C, Reed WD, Jefrey GP, Allan JE. (2003). Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol 70:219-227. (Pubitemid 36520630)
30. Mahmood I, Green MD. (2007). Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 47:1540-1554. (Pubitemid 350115304)
31. Mano Y, Usui T, Kamimura H. (2007). Te UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfbrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040-2044. (Pubitemid 350005193)
32. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. (2003). Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
33. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL, Kliewer SA. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122-15127. (Pubitemid 30337234)
34. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. (2008). Regulation of drug-metabolizing enzymes and transporters in infection, infammation, and cancer. Drug Metab Dispos 36:205-216. (Pubitemid 351185732)
35. Nakai K, Tanaka H, Hanada K, Ogata H, Suzuki F, Kumada H, Miyajima A, Ishida S, Sunouchi M, Habano W, Kamikawa Y, Kubota K, Kita J, Ozawa S, Ohno Y. (2008). Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fbrosis in chronic hepatitis C patients. Drug Metab Dispos 36:1786-1793.
36. Pageaux GP, le Bricquir Y, Berthou F, Bressot N, Picot MC, Blanc F, Michel H, Larrey D. (1998). Efects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 10: 491-495. (Pubitemid 28306542)
37. Petzinger E, Geyer J. (2006). Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch Pharmacol 372:465-475.
38. Poizot-Martin I, Marimoutou C, Benhaim S, Drogoul-Vey MP, Dinh T, Vion-Dury F, Frixon-Marin V, Tamalet C, Gastaut JA. (2003). Efcacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment. HIV Clin Trials 4:262-268. (Pubitemid 36974716)
39. Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H, Strom S, Liu Y, El-Assal O, Gao B. (2002). Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122:1020-1034. (Pubitemid 34267285)
40. Rose ML, Rusyn I, Bojes HK, Germolec DR, Luster M, Turman RG. (1999). Role of Kupfer cells in peroxisome proliferator-induced hepatocyte proliferation. Drug Metab Rev 31:87-116. (Pubitemid 29106653)
41. Schäfer M, Schmidt F, Grunze H, Laakmann G, Loeschke K. (2001). [Interferon alpha-associated agranulocytosis during clozapine treatment. Case report and status of current knowledge]. Nervenarzt 72:872-875.
42. Shah I, Band J, Samson M, Young J, Robinson R, Bailey B, Lerner AM, Prasad AS. (1984). Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies. Am J Hematol 17:363-371. (Pubitemid 15201285)
43. Stanley LA, Adams DJ, Balkwill FR, Grifn D, Wolf CR. (1991). Diferential efects of recombinant interferon alpha on constitutive and inducible cytochrome P450 isozymes in mouse liver. Biochem Pharmacol 42:311-320.
44. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. (1998). How cells respond to interferons. Annu Rev Biochem 67:227-264. (Pubitemid 28411130)
45. Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD. (2004). Kupfer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32:359-363. (Pubitemid 38263895)
46. Tong Z, Chandrasekaran A, Jordan R, Markiewicz V, Li H, Xiang Q, Shen L, Scatina J. (2007). Efects of ertiprotafb on hepatic cytochrome P450 and peroxisomal enzymes in rats and dogs, and in rat and human primary hepatocytes. Xenobiotica 37: 1-18. (Pubitemid 46019700)
47. Wan L, Lin CW, Lin YJ, Sheu JJ, Chen BH, Liao CC, Tsai Y, Lin WY, Lai CH, Tsai FJ. (2008). Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med 12:876-888. (Pubitemid 351718067)
48. Wong SF, Jakowatz JG, Taheri R. (2005). Potential drug-drug interaction between interferon alfa-2b and gemfbrozil in a patient with malignant melanoma. Clin Ter 27:1942-1948. (Pubitemid 43293216)
49. Xie W, Evans RM. (2001). Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 276:37739-37742.